228
Participants
Start Date
July 30, 2025
Primary Completion Date
January 4, 2032
Study Completion Date
January 4, 2032
Pembrolizumab
IV infusion
I-DXd
IV infusion
Leucovorin
IV infusion
Levoleucovorin
IV infusion
5-Fluorouracil (5-FU)
IV Infusion
Oxaliplatin
IV infusion
RECRUITING
National Cheng Kung University Hospital ( Site 1001), Tainan City
RECRUITING
Hopitaux Universitaires de Geneve HUG. ( Site 1701), Geneva
RECRUITING
Kantonsspital Graubuenden ( Site 1700), Chur
RECRUITING
Ramathibodi Hospital ( Site 1103), Ratchathewi
RECRUITING
Taipei Veterans General Hospital ( Site 1005), Taipei
RECRUITING
Istituto Oncologico Veneto IRCCS ( Site 9202), Padua
RECRUITING
CHU Lille - Institut Coeur Poumon ( Site 9100), Lille
RECRUITING
National Taiwan University Hospital ( Site 1000), Taipei
RECRUITING
Beijing Cancer Hospital ( Site 9500), Beijing
RECRUITING
Xuzhou Central Hospital ( Site 9512), Xuzhou
RECRUITING
The Second Affiliated Hospital of Anhui Medical University ( Site 9511), Hefei
RECRUITING
The First Affiliated Hospital of Nanchang University ( Site 9505), Nanchang
RECRUITING
The First Affiliated Hospital of Xiamen University ( Site 9503), Xiamen
RECRUITING
Henan Cancer Hospital ( Site 9509), Zhengzhou
RECRUITING
Liga Norte Riograndense Contra o Cancer ( Site 1301), Natal
RECRUITING
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 9000), Brno
RECRUITING
Aichi Cancer Center ( Site 9702), Nagoya
RECRUITING
National Cancer Center Hospital East ( Site 9701), Kashiwa
RECRUITING
National Cancer Center Hospital ( Site 9700), Chūō
RECRUITING
Oslo Universitetssykehus Radiumhospitalet ( Site 1501), Oslo
RECRUITING
Asan Medical Center ( Site 9901), Seoul
Collaborators (1)
Daiichi Sankyo
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY